PPD DEVELOPMENT LP - BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.
Key Details
Description
BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.
Context & Analysis
On Nov 12, 2025, Department of Health and Human Services obligated $117,399,278 to PPD DEVELOPMENT LP for barda will implement a randomized, double-blind, placebo-controlled, multicenter phase 2 trial in the us to evaluate the safety and efficacy of novel host-directed therapeutic candidates in hospitaliz…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost plus incentive fee contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in WILMINGTON, NC. The contract is scheduled through Sep 30, 2030. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.